(Total Views: 640)
Posted On: 01/17/2020 1:01:08 AM
Post# of 153905
I agree with you.
If NP can secure $40-50m in non-dilutive finding, that will bode well for current and future licensing agreements. CYDY won’t have to accept low ball offers and can ask for more of a percentage of the sales.
Like I’ve said before, and like others have said, cancer can be the homerun for CYDY and be very profitable (pending further clinical proof). I believe NO is working a plan to make as much of the revenue as possible from cancer stay in CYDYs pockets. Maybe profits from combo sales will help fund cancer trials and eventually assist CYDY in going the oncology indication alone. If leronlimab works as it has, in a couple of different metastatic cancers, the drug will sell itself.
If NP can secure $40-50m in non-dilutive finding, that will bode well for current and future licensing agreements. CYDY won’t have to accept low ball offers and can ask for more of a percentage of the sales.
Like I’ve said before, and like others have said, cancer can be the homerun for CYDY and be very profitable (pending further clinical proof). I believe NO is working a plan to make as much of the revenue as possible from cancer stay in CYDYs pockets. Maybe profits from combo sales will help fund cancer trials and eventually assist CYDY in going the oncology indication alone. If leronlimab works as it has, in a couple of different metastatic cancers, the drug will sell itself.
(3)
(0)
